Data from a phase 2 study looks promising.
The clinical-stage biotech made a new friend.
A trio of news items has the healthcare company in transition.
Data from a pair of clinical trials sent shares of the oncology drugmaker higher.
The bioterrorism expert finally completed its smallpox vaccine contract with the U.S. government.
A Denmark-based drugmaker thought the biotech was too cheap to pass up.
A licensing deal gives investors confidence in a turnaround.
The biotech’s pipeline is shrinking, but investors should focus on what will drive near-term value.
Unexpected phase 3 clinical trial data has investors smiling.
Unfortunately, there were more of the latter.
The Medicines Company Is Up 161% Year to Date, but Here's a Better Way to Play the Drugmaker's Success
Investors should go to the source.
Solid data for two pipeline candidates increases investors' confidence in the cancer biotech.
GLP-1 drugs keep getting easier to take.
In an unprecedented move, the agency is doing some of the legwork for the companies.
Patents and monopolies don’t always go hand in hand.
Investors are jumping in ahead of a data presentation tomorrow.
The biotech’s gene therapy isn’t helping patients see better.
The cannabis-focused biotech couldn’t hold its post-earnings gains.
Down over 18%, the biotech bounces back.
Investors continue to worry about decelerating growth at the orthodontic-device specialist.